EU Urged to Formulate Robust Response to US Drug Pricing Threats

Patient groups and the generic medicines sector are urging the European Union to formulate a robust response to potential drug pricing threats from the incoming Trump administration. Industry stakeholders contend that a unified European stance is necessary to counter any 'divide and conquer' approaches from Washington, according to a report titled Patients and generics sector urge EU to react to Trump’s drug pricing threats.

Health insurers have highlighted that EU unity can effectively counter Washington's strategy, particularly concerning pharmaceutical industry negotiations. The focus is on preparing for potential demands related to drug pricing, which could impact healthcare policy across the bloc.

The need for a cohesive European approach is underscored by ongoing research into the enforcement of EU competition law within the pharmaceutical sector. The COMPHACRISIS project, supervised by Professor Imelda Maher at University College Dublin (UCD), is examining the significant differences in EU competition law and policy enforcement during normal, crisis, and post-crisis periods, drawing lessons from the COVID-19 pandemic. A key objective of this project is to design an effective health crisis competition law framework, which could prove instrumental in equipping the EU to respond to external pressures, such as those anticipated from the US regarding drug pricing.

Developing a clear and unified strategy is seen as essential to protect European patient access to affordable medicines and to safeguard the integrity of the EU's pharmaceutical market against external economic pressures. The sector's plea emphasizes the proactive development of policies to ensure stability and fairness in drug pricing negotiations.

What this means: The European Union is being called upon to develop a pre-emptive and unified strategy for pharmaceutical pricing, leveraging existing research on competition law, to protect its healthcare systems and industry from potential aggressive US trade tactics.